Latest News and Press Releases

Lenders have reduced the rate of interest on Alvotech's loan facility reflecting sustained operational improvements and strengthened financial performance

REYKJAVIK, ISLAND (26 juni 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, ”Bolaget”), ett globalt biofarmaceutiskt företag som specialiserar sig på utveckling och tillverkning av biosimilära läkemedel för...

REYKJAVIK (26. júní 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að bandaríska eignastýringarfyrirtækið GoldenTree Asset Management hafi boðist til að lækka vexti á langtímaskuldum...

REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Aðalfundur Alvotech S.A. („félagsins“) fór fram 25. júní 2025. Fundurinn var haldinn í Lúxemborg, á skrifstofu lögfræðistofunnar Arendt við Avenue John F. Kennedy 41A.   Allar tillögur á dagskrá...

The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of...

REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of...

Alvotech (NASDAQ: ALVO) og samstarfsaðilar félagsins, Kashiv Biosciences og Advanz Pharma, kynntu í dag að jákvæð niðurstaða hefði náðst í klínískri rannsókn sem bar saman virkni AVT23, fyrirhugaðrar...

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines...

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...